NasdaqGS:ARWR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Arrowhead Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ARWR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.5%

ARWR

2.0%

US Biotechs

2.3%

US Market


1 Year Return

70.2%

ARWR

27.6%

US Biotechs

6.7%

US Market

Return vs Industry: ARWR exceeded the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: ARWR exceeded the US Market which returned 6% over the past year.


Shareholder returns

ARWRIndustryMarket
7 Day2.5%2.0%2.3%
30 Day26.6%7.4%-0.7%
90 Day33.6%25.3%17.1%
1 Year70.2%70.2%28.8%27.6%9.0%6.7%
3 Year2800.6%2800.6%34.6%30.2%36.7%27.8%
5 Year558.7%558.7%-3.3%-8.8%65.2%46.9%

Price Volatility Vs. Market

How volatile is Arrowhead Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arrowhead Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

15.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ARWR ($45.25) is trading below our estimate of fair value ($53.51)

Significantly Below Fair Value: ARWR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ARWR is poor value based on its PE Ratio (461.6x) compared to the Biotechs industry average (19.7x).

PE vs Market: ARWR is poor value based on its PE Ratio (461.6x) compared to the US market (16.1x).


Price to Earnings Growth Ratio

PEG Ratio: ARWR is poor value based on its PEG Ratio (8.7x)


Price to Book Ratio

PB vs Industry: ARWR is overvalued based on its PB Ratio (9.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Arrowhead Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

53.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARWR's forecast earnings growth (53% per year) is above the savings rate (2.2%).

Earnings vs Market: ARWR's earnings (53% per year) are forecast to grow faster than the US market (22.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ARWR's revenue (37.5% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ARWR's revenue (37.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ARWR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arrowhead Pharmaceuticals performed over the past 5 years?

49.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ARWR has high quality earnings.

Growing Profit Margin: ARWR's current net profit margins (6.9%) are lower than last year (10.5%).


Past Earnings Growth Analysis

Earnings Trend: ARWR has become profitable over the past 5 years, growing earnings by 49% per year.

Accelerating Growth: ARWR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ARWR had negative earnings growth (-4.3%) over the past year, making it difficult to compare to the Biotechs industry average (-4.5%).


Return on Equity

High ROE: ARWR's Return on Equity (1.9%) is considered low.


Next Steps

Financial Health

How is Arrowhead Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ARWR's short term assets ($314.5M) exceed its short term liabilities ($53.3M).

Long Term Liabilities: ARWR's short term assets ($314.5M) exceed its long term liabilities ($14.2M).


Debt to Equity History and Analysis

Debt Level: ARWR is debt free.

Reducing Debt: ARWR had no debt 5 years ago.

Debt Coverage: ARWR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ARWR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Arrowhead Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ARWR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARWR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ARWR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARWR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ARWR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Chris Anzalone (51yo)

12.58yrs

Tenure

US$2,216,264

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph.D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD2.22M) is below average for companies of similar size in the US market ($USD5.83M).

Compensation vs Earnings: Chris's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director12.58yrsUS$2.22m1.28% $59.1m
Kenneth Myszkowski
Chief Financial Officer10.42yrsUS$1.74m0.24% $10.9m
Patrick O'Brien
General Counsel & Corporate Secretary5.58yrsUS$1.55m0.10% $4.8m
Bruce Given
0.17yrUS$3.96m0.35% $16.1m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Curt Bradshaw
Chief Scientific Officer0.67yrno data0.12% $5.7m
Jane Davidson
Head of Human Resources & Administrationno datano datano data
Vincent Anzalone
Vice President of Investor Relationsno datano datano data
Susan Boynton
Senior Vice President of Regulatory Affairs0.83yrno datano data
Howard Lovy
Director of Communications14.92yrsno datano data

5.6yrs

Average Tenure

55yo

Average Age

Experienced Management: ARWR's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director12.58yrsUS$2.22m1.28% $59.1m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Douglass Given
Chairman of the Boardno dataUS$525.56k0.14% $6.6m
Michael Perry
Independent Lead Directorno dataUS$522.93k0.084% $3.8m
William Waddill
Independent Director2.5yrsUS$436.98k0.020% $927.5k
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno datano datano data
Mauro Ferrari
Independent Director9.92yrsUS$302.17k0.033% $1.5m
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Johnson Lau
Member of Hepatitis B Clinical Advisory Boardno datano datano data

9.9yrs

Average Tenure

61yo

Average Age

Experienced Board: ARWR's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ARWR insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.


Top Shareholders

Company Information

Arrowhead Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arrowhead Pharmaceuticals, Inc.
  • Ticker: ARWR
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.605b
  • Shares outstanding: 101.77m
  • Website: https://arrowheadpharma.com

Number of Employees


Location

  • Arrowhead Pharmaceuticals, Inc.
  • 177 East Colorado Boulevard
  • Suite 700
  • Pasadena
  • California
  • 91105
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARWRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2004
HDP1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2004
0HI3LSE (London Stock Exchange)YesCommon StockGBUSDJan 2004

Biography

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/08 23:57
End of Day Share Price2020/07/08 00:00
Earnings2020/03/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.